- In April 2025, trials showed that a non-hormonal male contraceptive implant, named Adam, can last for at least two years. The implant, which is inserted into the sperm ducts, blocks sperm from mixing with semen. It offers a reversible alternative to methods like condoms or vasectomies. Early results indicate its effectiveness for 24 months without adverse effects, though additional data on reversibility is still awaited. Further trials are planned to confirm long-term outcomes
- In March 2025, Daré Bioscience introduced Ovaprene, a non-hormonal, monthly contraceptive combining a barrier ring with a drug-releasing component. The device, inserted vaginally, releases an iron-based compound that impairs sperm motility, while its polymer mesh physically blocks sperm entry. Currently undergoing Phase 3 trials, Ovaprene aims to offer a non-hormonal alternative to traditional methods like hormonal IUDs and daily pills
- In September 2024, CooperSurgical introduced a new single-hand inserter for its Paragard intrauterine copper contraceptive (IUD), recently approved by the U.S. Food and Drug Administration (FDA). This innovative inserter is designed to simplify the insertion process, enhancing accessibility for healthcare providers and patients alike. Paragard has been a trusted option for over 30 years, offering more than 99% efficacy in preventing pregnancy for up to 10 years
- In June 2024, Contraline partnered with DNA Diagnostics Center (DDC) to enhance its ADAM male contraceptive trial. DDC provided an at-home sperm analysis test, enabling participants to monitor the implant's effectiveness privately. This collaboration aimed to improve participant compliance and provide real-time feedback on sperm presence, complementing the hydrogel implant's role in blocking sperm flow through the vas deferens
